and included in the analysis (follow-up rate 88.4%): 10,626 of the patients were men and 3,186 were women. Diagnosis at the time of registration was AMI for 2,955 patients, old myocardial infarction (MI) for 3,913 patients and unstable angina pectoris for 2,049 patients; 2,318 of the AMI patients were men, and 637 were women. Patients were followed up for an average of 2.7 years.
Data Registration and Accumulation
All follow-up data were registered electronically over the Web, details of which have been described previously. 1 Briefly, a central database server was set up and the patients' clinical information was sent to the central computer through a Web-based interface. Diagnosis of CAD at the time of registration was performed by the attending physician according to the manual distributed prior to the start-up of the study. The brand names and dosages of all the drugs that the patients were taking were registered by the attending physicians. The definition of each risk factor was as follows: smoking, at least 1 incident of smoking 2 years before registration; hyperlipidemia, serum total cholesterol of 220 mg/dl or more and/or low-density lipoprotein-cholesterol of 140 mg/dl or more and/or triglycerides of 150 mg/dl or more; impaired fasting glycemia (IFG), including diabetes mellitus, fasting blood glucose of 110mg/dl or more; hypertension, systolic blood pressure of 140mmHg or more and/or diastolic blood pressure of 90 mmHg or more; obesity, body mass index of 25 or more; familial history, CAD in any firstdegree relative; drinking, habit of alcohol consumption. These data were obtained from each patient by the attending physicians. Careful attention was paid to data security.
Investigations
The endpoint used in this report is a composite of allcause death and cardiovascular events, defined as the occurrence of fatal and nonfatal MI, fatal and nonfatal stroke, other cardiovascular events and death of any cause as a first event. All events were judged and registered by the attending physicians.
Ethical Considerations
The protocol of this study was approved by the Central Institutional Review Board of the University of Tokyo. Written informed consent was given by all patients.
Statistical Analysis
Kaplan-Meier hazard rates were calculated by univariate Cox regression analysis to examine incidence over time. Multivariate Cox regression analysis was performed to adjust for various factors. Covariates to be included were decided mainly by clinical significance, although those which showed multi-colinearity were excluded. Data for patients who were lost to follow-up were censored at the time of the last contact. Medication at the time of leaving hospital was used for analysis, which was performed on the assumption that medication did not change through the follow-up period (intention-to-treat principle). In observational studies, it is impossible to control covariates between the control group and treatment group, which can lead to biased estimates of the treatment effect of drugs. Propensity score analysis was performed so that, by taking the conditional probability of being treated using covariates into account, the covariates in the 2 groups could be balanced and therefore reduce the bias. 4 For each patient, a propensity score indicating the likelihood of being prescribed the drug class was calculated by multivariate logistic regression analysis. All background characteristics and medication data were included, except for the drug class being calculated, in the analysis. The patients were stratified into 5 groups according to the propensity scores and a stratified Cox regression model with propensity score strata as the stratification factor was used to calculate the hazards of each drug class.
Statistical analysis was performed with SAS version 9.1 (SAS Institute Inc, Cary, NC, USA).
Results

Background Characteristics and Medication Data
Background characteristics and medication data of the whole cohort, AMI subgroup and non-AMI subgroup are shown in Table 1 . As for the whole cohort, the ratios for each drug class were as follows: statins, 36.7%; fibrates, 3.2%; calcium-channel blockers (CCB), 50.2%; angiotensinconverting enzyme inhibitors (ACEI), 31.6%; angiotensin II receptor blockers (ARB), 13.5%; -blockers, 19.5%; antithrombotics, 87.2%; nitrates, 60.2%. The p value was calculated using the Kruskal-Wallis test for age and number of affected arteries and chi-square test was used for all other variables. Significant difference was observed in all variables, except family history, between the AMI subgroup and non-AMI subgroup.
Kaplan-Meier Analysis of Each Drug Class
Kaplan-Meier analysis was conducted for each drug class and the results are shown in Fig 1. Hazard ratios (HR) and confidence intervals (CI) were calculated using univariate Cox regression analysis. For statins and fibrates, the event rate was lower: HR for statins was 0.780 (95%CI, 0.710-0.856; p<0.001) and that of fibrates was 0.580 (95%CI, 0.425-0.790; p=0.001). For other drug classes, there was no significant difference in the event rate between those who took the drugs and those who did not, except for 1- 
Cox Regression Analysis of the Whole Cohort
In order to adjust for various factors, such as background characteristics and medications, Cox regression analysis was conducted (Table 2) ; 1,556 patients were excluded from the final calculation because of missing data. Of the background characteristics, higher age, IFG (diabetes mellitus was included in this study), hypertension, comorbidity of CHF, significant stenosis in the left main trunk (LMT), and a higher number of affected coronary arteries were all significantly associated with a worse outcome. As for the drug classes, statins and fibrates were significantly associated with a favorable outcome.
Cox Regression Analysis of Patients Who Presented With AMI
The result of the Cox regression analysis performed on the subgroup of patients who presented with AMI is shown in Table 3 ; 321 patients were excluded from the final calculation because of missing data. Higher age, CHF, LMT dis- Tables 1,2. ease, and higher number of affected coronary arteries were significantly associated with a worse outcome. Of the drug classes, CCB was associated with a worse outcome and antithrombotics was associated with a favorable outcome.
Propensity Score Analysis
A propensity score for each patient for each drug class was calculated by multivariate logistic regression analysis, taking background data and other medications into account. The patients were stratified into 5 groups according to the propensity scores and a stratified Cox regression model with propensity score strata as the stratification factor was used to calculate the HR of each drug class. The result for the whole cohort is shown in Table 4 and that for patients who presented with AMI is shown in Table 5 .
Discussion
Despite the high activity of Japanese cardiologists, actual data are scarce regarding the modes of treatment and their outcome in Japan, which translates into a situation where Japanese cardiologists depend on guidelines devised in Western countries. However, there are several known differences between the Western and Japanese populations, 5, 6 which should be taken into account when treating CAD patients and which led us to conduct a large scale follow-up study of patients with significant CAD in order to construct a database of their background data, medical treatments and outcomes.
The prescription pattern for CAD patients in Japan is thought to be different from that of Western countries. As is shown in Table 1 , while over 50% of patients were prescribed CCBs, only a little under 20% of patients were prescribed -blockers. When compared with reports from Western countries, several prominent differences are observed. 7 Beta-blockers are more likely to be prescribed than CCBs for CAD patients in Western countries, which may be because Japanese are more susceptible to vasospastic angina than Westerners, 6 and for which -blockers are contraindicative and CCBs are indicative. Other differences include the prescription rate of ACEIs and ARBs. Although ACEIs and ARBs are similar in that both drug classes inhibit the renin -angiotensin -aldosterone system, which is important for the treatment of cardiovascular diseases 8 in Japanese and Westerners alike, the prescription rate of ARB is lower in Western countries than in Japan because of the high cost. The reason for the relatively high prescription rate of ARBs in Japan might be attributed to the fact that East Asians, including Japanese, are more susceptible to the adverse effect of cough caused by ACEIs, 9,10 which might have resulted in a relatively fast switchover from ACEIs to ARBs in Japan. However, whether the difference in drug responses is solely the result of genetic differences between Japanese and Westerners is open to question and it can be argued that differences in the severity of coronary atherosclerosis or food may play a role. As for antithrombotics and lipid-lowering drugs, the prescription rate was similar.
When each drug class was analyzed for cumulative hazard without adjustment by various confounding factors, statins and fibrates showed a beneficial effect for CAD patients, whereas 1-blockers and nitrates showed a deleterious effect and the other drug classed showed no significant effect on the rate of cardiovascular events (Fig 1) .
Cox regression analysis was performed to take various confounding factors into account, including background risk factors and medication pattern. The result regarding the whole cohort is shown in Table 2 . In agreement with previous reports, 11 age, IFG, and hypertension were risk factors for cardiovascular events. The severity of heart disease, such as CHF, number of affected coronary arteries, and LMT disease was also risk factors. When adjusted for various factors, statins and fibrates still remained beneficial for CAD patients. Nitrates were not deleterious after adjustment by confounding factors; however, even after adjustment, ACEIs, ARBs and -blockers were not shown to be significantly beneficial in CAD patients against cardiovascular events. The result of the propensity score analysis for the whole cohort is shown in Table 4 . The results for all drugs, except the antithrombotics, did not show significant differences between Cox regression analysis and propensity analysis. Although the HR of antithrombotics was 0.893 (95%CI, 0.749-1.064; p=0.205) by Cox regression analysis, it was 0.799 (95%CI, 0.698-0.914; p=0.001) when the propensity score was considered, which suggests that when adjusted for treatment selection bias, beneficial effects of antithrombotics in CAD patients are more clearly shown. That ACEIs, ARBs and -blockers were not shown to be significantly beneficial suggests there were deleterious confounding factors that were not observed in the study and hence not included in the analysis. The clinical course of AMI patients is known to differ from that of other acute coronary syndrome patients, which led us to perform a Cox regression analysis on a subgroup of patients who presented with AMI. The result is shown in Table 3 and several changes from the whole cohort analysis are observed. As for background characteristics, IFG and hypertension had no significant effects on the cardiovascular event risks in this subgroup. With regard to drugs, those taking statins and fibrates did not have a significantly different outcome from those who did not. Those taking CCB had a worse outcome than those who did not (HR, 1.340; 95%CI, 1.084-1.655; p=0.007). Antithrombotics had a significantly favorable effect on the outcome (HR, 0.653; 95%CI, 0.443-0.963; p=0.031). Although not significant, those who took nitrates had a tendency for a favorable outcome compared with those who did not (HR, 0.862; 95%CI, 0.703-1.059; p=0.157). Propensity score analysis was also performed for this subgroup (Table 5) . Although the HR of nitrates was 0.862 (95%CI, 0.703-1.059; p=0.157) by usual Cox regression analysis, it was 0.820 (95%CI, 0.679-0.991; p=0.04) by propensity score analysis. Usually, nitrates are more likely to be given to patients with worse CAD profiles and the result of the propensity score analysis suggests that when adjusted for this treatment selection bias, the beneficial effect of nitrates are shown more clearly.
Several reasons may be attributed to the difference between the whole cohort and AMI-subgroup. As regards statins, previous reports suggest that they need to be initiated early after MI with a relatively intense therapeutic strategy. [12] [13] [14] [15] It may be that the initiation of statin therapy was slow and intensity of lipid lowering was not strong enough among this subgroup.
Short-acting CCBs, such as nifedipine, have been shown to be deleterious for the outcome of post-infarction patients, 16, 17 although other types of CCBs have not been shown to be harmful. 18, 19 In this study, short-acting CCBs were rarely used (data not shown), and future investigation may be required to elucidate the deleterious result obtained in this study.
There have been 2 reports that long-term nitrate therapy might be deleterious to patients after MI, 20,21 although both reports were observational studies and not randomized control studies. Randomized control studies conducted to examine the efficacy of nitrates have been sparse, but 1 showed that transdermal nitrates had a significant additional benefit when co-administered with ACEI in post-AMI patients. 22 In the subgroup of patients who presented with AMI in our cohort, nitrates tended to show a nonsignificant positive effect on outcome ( Table 3 ). The reasons for the discrepancy among studies are not very clear and necessitate randomized control studies in the future.
In conclusion, analysis of data from a large cohort of CAD patients in Japan revealed that the prescription pattern in Japan is different from that in Western countries, possibly because of difference in the patients' response to drugs. As regards to the effects of drugs, statins and fibrates were significantly beneficial. ACEIs, ARBs and antithrombotics were not shown to be significantly beneficial in the whole cohort, which might be ascribed to confounding factors not observed in the study. As for patients initially presenting with AMI, CCB showed a significantly deleterious effect and nitrates showed a nonsignificant tendency for beneficial effects, which should be investigated in future randomized control studies. Further analysis of the JCAD data itself will also be conducted in the future.
Study Limitations
This study was an observational study that intended to analyze the effects of medication on outcome, and like most observational studies with the same intent, it was affected by confounding by indication. 23 Although confounding factors were adjusted for by multivariate Cox regressional analysis, and the results were not contradictory to those obtained with propensity score analysis, some of the results observed in this study may require future randomized control studies to be confirmed.
